FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present data from multiple investigational studies for its first-in-class treatment VOQUEZNA® (vonoprazan) tablets at the American College of Gastroenterology (ACG) 2024…
Mon, 10 Mar 2025 23:40:00 GMT Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) had its price objective reduced by The Goldman Sachs Group from $18.00 to $12.00 in a research report sent to investors on Monday morning,Benzinga ...
Thu, 06 Mar 2025 09:13:00 GMT Hello, and welcome to the Phathom Pharmaceuticals Fourth Quarter and ... Earlier this morning, we issued a press release detailing the results we will be discussing during the call.
Thu, 06 Mar 2025 04:30:00 GMT VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 ...
Thu, 06 Mar 2025 01:10:00 GMT Ahead of this earnings release, the estimate revisions trend for Phathom Pharmaceuticals: mixed. While the magnitude and direction of estimate revisions could change following the company's ...
Wed, 05 Mar 2025 21:00:00 GMT FLORHAM PARK, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals ... Non-GAAP Financial Measures This press release includes financial results prepared in accordance with accounting ...
